Magnesium infusion in decompensated hypomagnesemic patients

Area of Science:

• Cardiology
• Biochemistry
• Pharmacology

Background:

• Severe cardiac decompensation (NYHA classes III-IV) is often associated with electrolyte imbalances.
• Hypomagnesemia can exacerbate cardiac dysfunction and contribute to diuretic side effects.
• Magnesium plays a crucial role in cardiac function and cellular metabolism.

Purpose of the Study:

• To assess the impact of intravenous magnesium sulphate on patients with severe cardiac decompensation and hypomagnesemia.
• To evaluate potential links between magnesium deficiency and diuretic-induced side effects.
• To observe the effect of magnesium supplementation on biochemical parameters and clinical symptoms.

Main Methods:

• Five patients with severe cardiac decompensation (NYHA III-IV) and hypomagnesemia received 25 mmol magnesium sulphate intravenously daily for one week.
• Biochemical parameters including serum calcium, urate, and blood glucose were monitored.
• Clinical symptoms such as leg cramps were assessed.

Main Results:

• Intravenous magnesium sulphate administration was generally well-tolerated in this small cohort.
• A slight decrease in serum calcium, urate, and blood glucose was observed during magnesium treatment.
• One patient experienced improvement in leg cramps following magnesium infusion.

Conclusions:

• Magnesium deficiency may contribute to side effects commonly observed during diuretic therapy.
• Intravenous magnesium sulphate may offer benefits in managing hypomagnesemia in cardiac decompensation.
• Further research is warranted to confirm these findings and elucidate the role of magnesium in diuretic-induced adverse events.